Additional benefits to be gained by the use of small molecule inhibitors of GSTO1-1 to regulate the expression of IL-1β include their low cost of production and their potentially short half-life relative to biologics such as canakinumab and rilonacept would allow their rapid withdrawal if a severe infection occurred. This evidence concerns the gene GSTO1 and infection.